Roivant Sciences Ltd.

ROIV · Healthcare · Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicine…

Roivant Sciences Ltd. (ROIV), in the Healthcare sector, has 48 disclosed filings on Paydirt over the trailing twelve months from 1 member of Congress and 12 corporate insiders: 1 purchase and 48 sales, 2 filed past the deadline (1 filing reported both). Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Nov 3 and filed Nov 5. The most active filer was Eric Venker with 14 filings. Data as of Nov 7 2026.

Add to watchlist

Filings, ttm

1 buy · 48 sells · 2 late

Traders, ttm

1 congress · 12 insiders

Volume, ttmiDollar value disclosed in the window

$778.2M

estimated for Congress, as filed for insiders

Median delay

execution to disclosure

Last traded

Nov 3

Filed Nov 5

ADViAverage daily dollar volume

$222.0M

market data

Share price · 12M

$38.88 (+83.7%)

Adjusted for splits and dividends.

Volume by month

Buys $16K Sells $1.1B

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed · past 24 months

Eric Venker President & Immunovant CEO 32 filings · 0 buys, 32 sales MS

Mayukh Sukhatme President & CIO 8 filings · 0 buys, 8 sales VR

Vivek Ramaswamy 10% owner 6 filings · 0 buys, 6 sales EB Epperly Melissa B, Director 4 filings · 0 buys, 4 sales MF

Meghan Fitzgerald Director 4 filings · 0 buys, 4 sales DG

Daniel Allen Gold Director 4 filings · 0 buys, 4 sales KM

Keith S Manchester Director 4 filings · 0 buys, 4 sales QL QVT Financial LP Other 4 filings · 0 buys, 4 sales

All 14 filers

Matthew Gline CEO 2 filings · 0 buys, 2 sales LM

Lisa McClain Representative (Spouse) 2 filings · 2 buys, 1 sale JH

Jennifer Humes Chief Accounting Officer 1 filing · 0 buys, 1 sale RK

Rakhi Kumar Chief Accounting Officer 1 filing · 0 buys, 1 sale RP

Richard Pulik CFO 1 filing · 0 buys, 1 sale FT

Frank Torti President and Vant Chair 1 filing · 0 buys, 1 sale

Recent filings

Eric VenkerSALE President & Immunovant CEO $7.3M
200,000 sh × $36.31
Exec Nov 3
Filed Nov 5 · 6:11 PM ET Eric VenkerSALE President & Immunovant CEO $7.3M
200,000 sh × $36.59
Exec Oct 28
Filed Oct 30 · 6:29 PM ET Eric VenkerSALE President & Immunovant CEO $7.0M
200,000 sh across 2 lots
Exec Oct 20
Filed Oct 22 · 6:44 PM ET Epperly Melissa B,SALE Director $608K
16,850 sh × $36.08
Exec Oct 1
Filed Oct 5 · 6:05 PM ET Eric VenkerSALE President & Immunovant CEO $7.3M
200,000 sh × $36.62
Exec Sep 30
Filed Oct 2 · 5:37 PM ET Epperly Melissa B,SALE Director $172K
4,338 sh × $39.65
Exec Sep 15
Filed Sep 17 · 6:43 PM ET Meghan FitzgeraldSALE Director $187K
4,712 sh × $39.68
Exec Sep 15
Filed Sep 17 · 6:42 PM ET Meghan FitzgeraldSALE Director $798K
20,000 sh × $39.90
Exec Sep 8
Filed Sep 10 · 9:00 PM ET Eric VenkerSALE President & Immunovant CEO $7.2M
200,000 sh across 2 lots
Exec Aug 28
Filed Sep 1 · 9:00 PM ET Mayukh SukhatmeSALE President & CIO $12.4M
335,174 sh across 3 lots
Exec Aug 19
Filed Aug 21 · 9:00 PM ET Mayukh SukhatmeSALE President & CIO $24.2M
664,826 sh across 4 lots
Exec Aug 14
Filed Aug 18 · 9:00 PM ET Eric VenkerSALE President & Immunovant CEO $7.0M
200,000 sh × $34.95
Exec Jul 27
Filed Jul 29 · 9:00 PM ET Meghan FitzgeraldSALE Director $349K
10,000 sh × $34.90
Exec Jun 30
Filed Jul 2 · 7:03 PM ET Epperly Melissa B,SALE Director $515K
15,002 sh × $34.32
Exec Jun 29
Filed Jul 1 · 6:34 PM ET QVT Financial LPSALE Other $49.4M
1,438,163 sh across 5 lots
Exec Jun 26
Filed Jun 30 · 5:30 PM ET Daniel Allen GoldSALE Director $49.4M
1,438,163 sh across 5 lots
Exec Jun 26
Filed Jun 30 · 5:30 PM ET Keith S ManchesterSALE Director $56.4M
1,638,163 sh across 6 lots
Exec Jun 26
Filed Jun 30 · 5:30 PM ET Mayukh SukhatmeSALE President & CIO $34.1M
1,000,000 sh across 2 lots
Exec Jun 25
Filed Jun 29 · 5:30 PM ET Eric VenkerSALE President & Immunovant CEO $6.6M
200,000 sh across 2 lots
Exec Jun 24
Filed Jun 26 · 5:30 PM ET Eric VenkerSALE President & Immunovant CEO $6.1M
200,000 sh × $30.27
Exec May 22
Filed May 22 · 5:30 PM ET Eric VenkerSALE President & Immunovant CEO $5.9M
200,000 sh × $29.59
Exec Apr 20
Filed Apr 22 · 5:30 PM ET Matthew GlineSALE CEO $8.4M
289,774 sh × $29.16
Exec Apr 16
Filed Apr 20 · 5:30 PM ET Jennifer HumesSALE Chief Accounting Officer $384K
13,538 sh × $28.37
Exec Apr 8
Filed Apr 10 · 5:30 PM ET Meghan FitzgeraldSALE Director $1.9M
70,000 sh × $27.45
Exec Mar 26
Filed Mar 30 · 5:30 PM ET Eric VenkerSALE President & Immunovant CEO $5.6M
200,000 sh × $28.24
Exec Mar 17
Filed Mar 19 · 5:30 PM ET